Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 71.4%
Negative

Neutral
Business Wire
5 days ago
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue micro.
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
Positive
Zacks Investment Research
24 days ago
BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.
BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Neutral
Seeking Alpha
24 days ago
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Positive
Zacks Investment Research
25 days ago
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
Bruker (BRKR) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.47 per share a year ago.
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
Neutral
Business Wire
25 days ago
Bruker Reports First Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bi.
Bruker Reports First Quarter 2026 Financial Results
Negative
Zacks Investment Research
1 month ago
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
Neutral
Business Wire
1 month ago
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presenta.
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Neutral
Business Wire
1 month ago
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. At AACR 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx.
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
Neutral
Business Wire
1 month ago
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati.
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
Neutral
Business Wire
1 month ago
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker's continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w.
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management